Sanofi (SNY)
After hours:
| Previous close | 46.98 |
| Open | 46.91 |
| Bid | 46.06 x 2200 |
| Ask | 47.27 x 900 |
| Day's range | 46.40 - 46.94 |
| 52-week range | 42.63 - 57.82 |
| Volume | |
| Avg. volume | 2,019,661 |
| Market cap | 117.87B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 11.77 |
| EPS (TTM) | 3.96 |
| Earnings date | N/A |
| Forward dividend & yield | 1.90 (4.04%) |
| Ex-dividend date | 30 May 2023 |
| 1y target est | 62.50 |
- Reuters
UPDATE 2-White House urges RSV immunization makers to meet demand
Senior Biden administration officials met with the makers of RSV immunizations for children this week to underscore the need for manufacturers such as Sanofi and AstraZeneca to urgently meet demand as winter approaches, the White House said on Tuesday. At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the immunizations targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults.
ZacksRegeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.
GlobeNewswireDupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL), confirming results from the landmark BOREAS pivotal trial Dupixent rapidly and significantly improved lung function (139 mL in FEV1) compared to placebo (57 mL in FEV1) at 12 weeks Supplemental BLA submission planned by end of 2023
